PCE

Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Episode Summary

In this podcast, an advanced practice provider discusses the latest guidance on integrating CDK4/6 inhibitors into treatment of early-stage and metastatic HR+/HER2- breast cancer. Cases from her practice illustrate how to approach treatment selection and manage important adverse events.

Episode Notes

In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:

• An overview of the monarchE study leading to FDA approval of adjuvant abemaciclib
• Key trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancer
• Managing adverse events associated with CDK4/6 inhibitors
• Promoting adherence to oral therapy

Presenter:

Julia LaBarbera, MSN, RN, AGACNP-BC
Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California

Link to full program:
PCE.is/Onc22